The condition previously known as polycystic ovary syndrome (pcos) has been renamed to polyendocrine metabolic ovarian syndrome (pmos). The name change is intended to better reflect the condition's multisystem nature and potentially improve diagnosis and care. The new name, pmos, may have implications for the health and treatment of women affected by the condition, which is reported to affect a large number of women worldwide.